{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:31:56Z","timestamp":1778772716897,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,4,2]],"date-time":"2015-04-02T00:00:00Z","timestamp":1427932800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1038\/hr.2015.46","type":"journal-article","created":{"date-parts":[[2015,4,2]],"date-time":"2015-04-02T05:56:53Z","timestamp":1427954213000},"page":"597-604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Therapeutic effects of udenafil on pressure-overload cardiac hypertrophy"],"prefix":"10.1038","volume":"38","author":[{"given":"Hack-Lyoung","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Pyo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyung-Kwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae-Won","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung-Hee","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Bae","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,4,2]]},"reference":[{"key":"BFhr201546_CR1","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2741\/1614","volume":"10","author":"DH Maurice","year":"2005","unstructured":"Maurice DH . Cyclic nucleotide phosphodiesterase-mediated integration of cGMP and cAMP signaling in cells of the cardiovascular system. Front Biosci 2005; 10: 1221\u20131128.","journal-title":"Front Biosci"},{"key":"BFhr201546_CR2","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1056\/NEJM199201093260203","volume":"326","author":"J Rajfer","year":"1992","unstructured":"Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ . Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992; 326: 90\u201394.","journal-title":"N Engl J Med"},{"key":"BFhr201546_CR3","doi-asserted-by":"publisher","first-page":"12944","DOI":"10.1074\/jbc.M404706200","volume":"280","author":"A Das","year":"2005","unstructured":"Das A, Xi L, Kukreja RC . Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 2005; 280: 12944\u201312955.","journal-title":"J Biol Chem"},{"key":"BFhr201546_CR4","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1161\/01.RES.0000066853.09821.98","volume":"92","author":"F Salloum","year":"2003","unstructured":"Salloum F, Yin C, Xi L, Kukreja RC . Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res 2003; 92: 595\u2013597.","journal-title":"Circ Res"},{"key":"BFhr201546_CR5","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1161\/01.CIR.0000160359.49478.C2","volume":"111","author":"PW Fisher","year":"2005","unstructured":"Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC . Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 2005; 111: 1601\u20131610.","journal-title":"Circulation"},{"key":"BFhr201546_CR6","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1161\/CIRCULATIONAHA.105.540500","volume":"112","author":"BA Borlaug","year":"2005","unstructured":"Borlaug BA, Melenovsky V, Marhin T, Fitzgerald P, Kass DA . Sildenafil inhibit beta-adrenergic-stimulated cardiac contractility in humans. Circulation 2005; 112: 2642\u20132649.","journal-title":"Circulation"},{"key":"BFhr201546_CR7","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1161\/CIRCULATIONAHA.111.065300","volume":"125","author":"KH Kim","year":"2012","unstructured":"Kim KH, Kim YJ, Ohn JH, Yang J, Lee SE, Lee S, Kim HK, Seo JW, Sohn DW . Long-term effects of sildenafil in a rat model of chronic mitral regurgitationbenefits of ventricular remodeling and exercise capacity. Circulation 2012; 125: 1390\u20131401.","journal-title":"Circulation"},{"key":"BFhr201546_CR8","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nm1175","volume":"11","author":"E Takimoto","year":"2005","unstructured":"Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA . Chronic inhibition of cyclic GMP phosphodiesterase 5\u2009A prevents and reverses cardiac hypertrophy. Nat Med 2005; 11: 214\u2013222.","journal-title":"Nat Med"},{"key":"BFhr201546_CR9","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/BF02977007","volume":"25","author":"H Doh","year":"2002","unstructured":"Doh H, Shin CY, Son M, Ko JI, Yoo M, Kim SH, Kim WB . Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch Pharm Res 2002; 25: 873\u2013878.","journal-title":"Arch Pharm Res"},{"key":"BFhr201546_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1365-2125.2009.03404.x","volume":"68","author":"TE Kim","year":"2009","unstructured":"Kim TE, Kim BH, Kim JR, Lim KS, Hong JH, Kim KP, Kim HS, Shin SG, Jang IJ, Yu KS . Effect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunction. B J Clin Pharmacol 2009; 68: 43\u201346.","journal-title":"B J Clin Pharmacol"},{"key":"BFhr201546_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/bdd.455","volume":"26","author":"HJ Shim","year":"2005","unstructured":"Shim HJ, Kim YC, Lee JH, Kwon JW, Kim WB, Kim YG, Kim YG, Kim SH, Lee MG . Interspecies pharmacokinetic scaling of DA-8159, a new erectrogenic, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics. Biopharm Drug Dispos 2005; 26: 269\u2013277.","journal-title":"Biopharm Drug Dispos"},{"key":"BFhr201546_CR12","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1002\/jps.10482","volume":"92","author":"HJ Shim","year":"2003","unstructured":"Shim HJ, Kim YC, Park KJ, Kim DS, Kwon JW, Kim WB, Lee MG . Pharmacokietics of DA-8159, a new electogenic, after intravenous and oral administration to rats: Hepatic and intestinal first-pass effects. J Pharm Sci 2003; 92: 2185\u20132195.","journal-title":"J Pharm Sci"},{"key":"BFhr201546_CR13","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1161\/01.RES.66.3.735","volume":"66","author":"PT Buser","year":"1990","unstructured":"Buser PT, Wikman-Coffelt J, Wu ST, Derugin N, Parmley WW, Higgins CB . Postischemic recovery of mechanical performance and energy metabolism in the presence of left ventricular hypertrophy. A 31\u2009P-MRS study. Circ Res 1990; 66: 735\u2013746.","journal-title":"Circ Res"},{"key":"BFhr201546_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/hr.2013.119","volume":"37","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Shao L, Ma A, Guan G, Wang J, Wang Y, Tian G . Telmisartan delaysmyocardial fibrosis in rats with hypertensive left ventricular hypertrophy by TGF-\u03b21\/Smad signal pathway. Hypertens Res 2014; 37: 43\u201349.","journal-title":"Hypertens Res"},{"key":"BFhr201546_CR15","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1161\/CIRCULATIONAHA.108.845792","volume":"123","author":"MH Drazner","year":"2011","unstructured":"Drazner MH . The progression of hypertensive heart disease. Circulation 2011; 123: 327\u2013334.","journal-title":"Circulation"},{"key":"BFhr201546_CR16","doi-asserted-by":"publisher","first-page":"e58841","DOI":"10.1371\/journal.pone.0058841","volume":"8","author":"S Vandenwijngaert","year":"2013","unstructured":"Vandenwijngaert S, Pokreisz P, Hermans H, Gillijns H, Pellens M, Bax NA, Coppiello G, Oosterlinck W, Balogh A, Papp Z, Bouten CV, Bartunek J, D'hooge J, Luttun A, Verbeken E, Herregods MC, Herijgers P, Bloch KD, Janssens S . Increased cardiac myocyte PDE5 levels in human and murine pressure overload hypertrophy contribute to adverse LV remodeling. PLoS ONE 2013; 8: e58841.","journal-title":"PLoS ONE"},{"key":"BFhr201546_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-2210-5-10","volume":"5","author":"MA Hassan","year":"2005","unstructured":"Hassan MA, Ketat AF . Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. BMC Pharmacol 2005; 5: 10.","journal-title":"BMC Pharmacol"},{"key":"BFhr201546_CR18","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1146\/annurev.immunol.19.1.683","volume":"19","author":"KW Moore","year":"2001","unstructured":"Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A . Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683\u2013765.","journal-title":"Annu Rev Immunol"},{"key":"BFhr201546_CR19","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1016\/S0195-668X(03)00480-9","volume":"24","author":"S Adamopoulos","year":"2003","unstructured":"Adamopoulos S, Parissis JT, Paraskevaidis I, Karatzas D, Livanis E, Georgiadis Karavolias G, Mitropoulos D, Degiannis D, Kremastinos DT . Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy. Eur Heart J 2003; 24: 2186\u20132196.","journal-title":"Eur Heart J"},{"key":"BFhr201546_CR20","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1161\/01.CIR.103.2.220","volume":"103","author":"L Gullestad","year":"2001","unstructured":"Gullestad L, Aass H, Fjeld JG, Wikeby L, Andreassen AK, Ihlen H, Simonsen S, Kjekshus J . Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001; 103: 220\u2013225.","journal-title":"Circulation"},{"key":"BFhr201546_CR21","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/S0008-6363(00)00003-1","volume":"46","author":"YY Li","year":"2000","unstructured":"Li YY, McTiernan CF, Feldman AM . Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 2000; 46: 214\u2013224.","journal-title":"Cardiovasc Res"},{"key":"BFhr201546_CR22","first-page":"972","volume":"40","author":"D Garcia","year":"2007","unstructured":"Garcia D, Pibarot P, Kadem L, Durand LG . Respective impacts of arotic stenosis and systemic hypertension on left ventricular hypertrophy. Hypertens 2007; 40: 972\u2013980.","journal-title":"Hypertens"},{"key":"BFhr201546_CR23","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.lfs.2005.06.042","volume":"78","author":"SM Choi","year":"2006","unstructured":"Choi SM, Kim JE, Kang KK . Chronic treatment of DA-8159, a new phosphodiesterase type V inhibitor, attenuates endothelial dysfunction in stroke-prone spontaneously hypertensive rat. Life Sci 2006; 78: 1211\u20131216.","journal-title":"Life Sci"},{"key":"BFhr201546_CR24","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/ijir.2009.2","volume":"21","author":"BH Chung","year":"2009","unstructured":"Chung BH, Lee JY, Lee SH, Yoo SJ, Lee SW, Oh CY . Safety and efficacy of the simultaneous administration of udenafil and an \u03b1-blcoker in men with erectile dysfunction concomitant with BPH\/LUTS. Int J Import Res 2009; 21: 122\u2013128.","journal-title":"Int J Import Res"},{"key":"BFhr201546_CR25","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.dld.2014.10.018","volume":"47","author":"W Kreisel","year":"2014","unstructured":"Kreisel W, Deibert P, Kupcinskas L, Sumskiene J, Appenrodt B, Roth S, Neagu M, R\u00f6ssle M, Zipprich A, Caca K, Ferlitsch A, Dilger K, Mohrbacher R, Greinwald R, Sauerbruch T . The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study. Dig Liver Dis 2014; 47: 144\u2013150.","journal-title":"Dig Liver Dis"},{"key":"BFhr201546_CR26","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1001\/archinte.162.12.1349","volume":"162","author":"HA Fink","year":"2002","unstructured":"Fink HA, Mac Donald R, Rutks IR, Nelson DB, Wilt TJ . Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2002; 162: 1349\u20131360.","journal-title":"Arch Intern Med"},{"key":"BFhr201546_CR27","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1111\/j.1365-2125.2008.03107.x","volume":"65","author":"BH Kim","year":"2008","unstructured":"Kim BH, Lim HS, Chung JY, Kim JR, Lim KS, Sohn DR, Cho JY, Yu KS, Shin SG, Pick JS, Jang IJ . Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. B J Clin Pharmacol 2008; 65: 848\u2013854.","journal-title":"B J Clin Pharmacol"},{"key":"BFhr201546_CR28","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1161\/01.CIR.0000099502.17776.C2","volume":"108","author":"ED Michelakis","year":"2003","unstructured":"Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, Archer SL . Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003; 108: 2066\u20132069.","journal-title":"Circulation"},{"key":"BFhr201546_CR29","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1016\/j.jacc.2007.07.078","volume":"50","author":"M Guazzi","year":"2007","unstructured":"Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD . Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007; 50: 2136\u20132144.","journal-title":"J Am Coll Cardiol"},{"key":"BFhr201546_CR30","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3109\/15412555.2012.694922","volume":"9","author":"JS Park","year":"2012","unstructured":"Park JS, Lim HJ, Cho YJ, Lee JH, Yoon HI, Lee CT . Udenafil improves exercise capacity in patients with chronic obstructive pulmonary disease: a prospective study. COPD 2012; 9: 499\u2013504.","journal-title":"COPD"},{"key":"BFhr201546_CR31","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1161\/hc3501.095215","volume":"104","author":"YY Li","year":"2001","unstructured":"Li YY, Feng Y, McTiernan CF, Pei W, Moravec CS, Wang P, Rosenblum W, Kormos RL, Feldman AM . Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart aftersupport with left ventricular assist devices. Circulation 2001; 104: 1147\u20131152.","journal-title":"Circulation"},{"key":"BFhr201546_CR32","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1084\/jem.20061943","volume":"204","author":"Y Jiang","year":"2007","unstructured":"Jiang Y, Reynolds C, Xiao C, Feng W, Zhou Z, Rodriguez W, Tyaqi SC, Eaton JW, Saari JT, Kang YJ . Dietary copper supplementation reverses hypertrophic cardiomyopathy induced by chronic pressure overload in mice. J ExpMed 2007; 204: 657\u2013666.","journal-title":"J ExpMed"},{"key":"BFhr201546_CR33","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S0140-6736(11)60894-5","volume":"378","author":"AM Shah","year":"2011","unstructured":"Shah AM, Mann DL . In search of new therapeutic targets and strategies for heartfailure: recent advances in basic science. Lancet 2011; 378: 704\u2013712.","journal-title":"Lancet"},{"key":"BFhr201546_CR34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/hr.2013.110","volume":"37","author":"Y Li","year":"2014","unstructured":"Li Y, Jiang H, Ruan C, Zhong J, Gao P, Zhu D, Niu W, Guo S . The interaction of transient receptor potential melastatin 7 with macrophages promotes vascular adventitial remodeling in transverse aortic constriction rats. Hypertens Res 2014; 37: 35\u201342.","journal-title":"Hypertens Res"},{"key":"BFhr201546_CR35","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/1745-6215-14-188","volume":"14","author":"KH Kim","year":"2013","unstructured":"Kim KH, Kim HK, Hwang IC, Lee SP, Cho HJ, Kang HJ, Kim YJ, Sohn DW . ULTIMATE-SHF trial [UdenafiL Therapy to Improve symptoMAtology, exercise Tolerance and hEmodynamics in patients with chronic systolic heart failure]: study protocol for a randomized, placebo-controlled, double-blind trial. Trials 2013; 14: 188.","journal-title":"Trials"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/hr201546.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr201546","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr201546.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:15:35Z","timestamp":1684430135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/hr201546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,2]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["BFhr201546"],"URL":"https:\/\/doi.org\/10.1038\/hr.2015.46","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,2]]},"assertion":[{"value":"6 August 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}